Skip to main
  1. Stocks
  2. Nuvectis Pharma
  3. Forecast
NVCT

Nuvectis Pharma (NVCT) Stock Forecast & Price Target

Nuvectis Pharma (NVCT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvectis Pharma is attractive because its pipeline is increasingly de-risked by clinical validation in two differentiated programs, led by NXP100 and NXP200, while NXP900 adds further optionality. NXP100 has already generated robust China data in PNH, including 59.5% of treated patients achieving hemoglobin ≥12 g/dL without transfusion versus 8.3% for eculizumab, and positive IgAN results, supporting a once-daily oral Factor B inhibitor in large, validated markets. NXP200’s Breakthrough Therapy Designation in China, greater than 40% response rate in glioma, and $20M upfront licensing structure reinforce the company’s ability to advance precision oncology assets with meaningful regulatory, commercial, and long-duration patent support through 2042 and 2043.

Bears say

Nuvectis Pharma is facing a financing risk profile that could pressure existing shareholders, because it may need to raise significant capital to advance later-stage programs for NXP100 beyond PNH and C3G, as well as NXP200 and NXP900. The prospect of additional equity raises is especially concerning in a company with a narrow oncology pipeline, since dilution could be required before the assets generate meaningful clinical or commercial value. Fundamental execution risk is also elevated by limited efficacy for CFD inh, along with safety signals including infusion-related reactions at 15.6% versus 13.0%, one life-threatening thrombocytopenia event, and one fatal ischemic stroke.

Nuvectis Pharma (NVCT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvectis Pharma and is not a guaranteed prediction by Public.com or investment advice.

Nuvectis Pharma (NVCT) Analyst Forecast & Price Prediction

Get the latest Nuvectis Pharma (NVCT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Nuvectis Pharma (NVCT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvectis Pharma (NVCT) Forecast

Analysts have given Nuvectis Pharma (NVCT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Nuvectis Pharma (NVCT) has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvectis Pharma (NVCT)


Nuvectis Pharma (NVCT) Analyst Forecast & Price Prediction

Get the latest Nuvectis Pharma (NVCT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Nuvectis Pharma (NVCT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NVCT stock data and trends